Skip Navigation

Correction for Garber, J. Natl. Cancer Inst. 97 (6) 412-413.
JNCI Journal of the National Cancer Institute 2005 97(7):480; doi:10.1093/jnci/97.7.480-a
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

Correction

Due to a typesetter's error, the incorrect version of the third paragraph from the end of "Tamoxifen Pharmacogenetics Moves Closer to Reality" (Vol. 97, No. 6, p. 412) was printed. The fourth sentence should read as follows: "He points out that the response rate for Herceptin (trastuzumab) is only 25%, even for patients with multiple copies of the Her-2/neu gene."


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?